This document discusses research on new epigenetic biomarkers for oropharyngeal cancer. Specifically, it finds that differential DNA methylation can predict tumor behavior and identify new therapeutic targets. A 150-CpG and 125-CpG signature was found to accurately predict aggressive disease within 24 months and nodal metastasis at diagnosis, respectively. Further validation of these predictive signatures in external patient populations could lead to a clinically useful test for treatment selection.